Skip to search formSkip to main contentSkip to account menu

ARRY 142886

Known as: ARRY-142886, ARRY142886 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AZD 6244Pharmacologic Substance
selumetinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
10503Background: PN in NF1 can cause substantial morbidity, and there are no approved medical therapies. In a phase I trial of… 
2015
2015
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer
SummaryPurposeKRAS is frequently mutated in non-small cell lung cancers (NSCLC), resulting in activation of the MEK/ERK pathway… 
2013
2013
Predictive Biomarkers and Personalized Medicine Phase II Trial of MEK Inhibitor Selumetinib ( AZD 6244 , ARRY-142886 ) in Patients with BRAFV 600 E / K-Mutated Melanoma
Purpose: Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be… 
2013
2013
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
SummaryThis study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated… 
2013
2013
Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inihibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with irinotecan (IRI): An AGICC study.
380 Background: 2nd-line therapy of KRASm CRC is limited; targeting downstream signal transduction enzymes is rational here. Use… 
2010
2010
Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements.
5536 Background: There is no standard treatment for IRPTC. AZD6244 is an oral, small molecule inhibitor of the mitogen-activated… 
2009
2009
Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models
The ERK and mTOR pathways show multiple interconnections that coordinate growth activation and the regulation of protein… 
2008
2008
Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)
8029 Background: The Raf/MEK/ERK signaling pathway is necessary for oncogenic function, and in NSCLC pts constitutive activation… 
2008
2008
AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy
• No standard of care exists for patients who experience disease progression after treatment with oxaliplatin/irinotecan-based… 
2005
2005
Validation and use of a biomarker for clinical development of the MEK1/2 inhibitor ARRY-142886 (AZD6244)
3075 Background: Optimal transition of a signal transduction inhibitor from discovery into clinical development requires a robust… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)